Research programme: autoimmune disease and inflammation therapies - Ascentia/University of Washington
Latest Information Update: 27 Mar 2008
At a glance
- Originator University of Washington
- Developer Ascentia Biomedical Corporation
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Autoimmune disorders; Psoriasis
Most Recent Events
- 31 Aug 2005 Preclinical trials in Asthma in USA (unspecified route)
- 31 Aug 2005 Preclinical trials in Psoriasis in USA (unspecified route)
- 31 Aug 2005 Preclinical trials in Autoimmune disorders in USA (unspecified route)